BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

Exscientia

Exscientia logo

Website
https://www.exscientia.co.uk/
Founded
2012

Technologies

AI Companies (Drug Discovery) Antibody Discovery Companies Pharmaceutical and Drug Discovery

At the forefront of small molecule drug discovery

We are the first company to automate drug design, surpassing conventional human endeavour.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

bispecific drugs polypharmacology drug design


Articles Mentioning This Company

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

Nov. 26, 2025     Articles
Development of a novel drug is a tedious process that requires immense investments of resources and time—on average, it takes from 8-10 years and capitalized R&D costs are reported between ~$1.1B median and ~$2.2B+ per asset in large-pharma cohorts for a new medicine to complete the journey from initial discovery …
13 Publicly Traded AI-driven Drug Discovery Companies

14 Biotechs Utilizing AI-based Research Platforms

Nov. 11, 2025     Articles
According to our internal database, more than 500 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies in the life sciences, in particular, in drug discovery.  Some companies are incorporating AI tools to …

11 Biopharma Trends to Watch in 2024

March 14, 2024     Business Intelligence
2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

R&D Platform

ML for predicting ADME, novelty, synthetic accessibility, pharmacology of molecules. Single and multi-target prediction. Developed a (lead candidate) bispecific, dual-agonist compound that selectively activates two GPCR families -- for Sumitomo pharma (end of 2015)

News

  • 2024-08-08
    Breaking: In Arguably the Largest AI in Bio Deal, Recursion Acquires UK-based "End-to-End" AI Biotech Exscientia
  • 2024-04-03
    New Landmark Report Unveils a Decade of AI Transformation in Drug Discovery
  • 2024-02-07
    Exscientia Launches New Clinical Study to Enhance Cancer Treatment Through AI

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.